Roger Härtl1, Alexander Joeris2, Robert A McGuire3. 1. Department of Neurological Surgery, Weill Cornell Brain and Spine Center, Weill Cornell Medical College, New York-Presbyterian Hospital, 525 East 68th Street, Box 99, New York, NY, 10021, USA. roh9005@med.cornell.edu. 2. AO Clinical Investigation and Documentation, Dübendorf, Switzerland. 3. Department of Orthopedics and Rehabilitation, University of Mississippi Medical Center, Jackson, USA.
Abstract
PURPOSE: To review the evidence on safety of anterior lumbar interbody fusion (ALIF) and extreme lateral transpsoas interbody fusion (ELIF) in the treatment of degenerative spinal disorders with an emphasis on the association between neuromonitoring and complications. METHODS: We performed a systematic literature search in the Cochrane (CENTRAL), MEDLINE, EMBASE and the FDA Medical Devices databases. We abstracted information on study design, sample size, population, procedure, number and location of involved levels, follow-up time and complications, as well as information on conflict of interest and source of funding. In addition, for ELIF we collected information on the use of neuromonitoring during the procedure. RESULTS: 34 publications were included in the review: 24 ELIF (all case series), 9 ALIF (8 randomized controlled trials and 1 case series) and one retrospective cohort that directly compared ELIF with ALIF. 18 out of 24 ELIF studies reported using neuromonitoring. The overall complication rate for ELIF was lower compared to ALIF without FDA reports (16.61 vs. 26.47 %, respectively). However, the rate of neurologic complications in ELIF was almost twice as high compared to ALIF without FDA reports (8.92 and 4.96 %, respectively). The rate of overall complications in ELIF studies that were reported using neuromonitoring was lower compared to the studies that did not report using neuromonitoring (16.34 vs. 21.74 %, respectively). CONCLUSION: Although the overall complications rate for ELIF was lower compared to ALIF, ELIF is associated with a greater risk of neurological complications compared to ALIF even when used with neuromonitoring.
PURPOSE: To review the evidence on safety of anterior lumbar interbody fusion (ALIF) and extreme lateral transpsoas interbody fusion (ELIF) in the treatment of degenerative spinal disorders with an emphasis on the association between neuromonitoring and complications. METHODS: We performed a systematic literature search in the Cochrane (CENTRAL), MEDLINE, EMBASE and the FDA Medical Devices databases. We abstracted information on study design, sample size, population, procedure, number and location of involved levels, follow-up time and complications, as well as information on conflict of interest and source of funding. In addition, for ELIF we collected information on the use of neuromonitoring during the procedure. RESULTS: 34 publications were included in the review: 24 ELIF (all case series), 9 ALIF (8 randomized controlled trials and 1 case series) and one retrospective cohort that directly compared ELIF with ALIF. 18 out of 24 ELIF studies reported using neuromonitoring. The overall complication rate for ELIF was lower compared to ALIF without FDA reports (16.61 vs. 26.47 %, respectively). However, the rate of neurologic complications in ELIF was almost twice as high compared to ALIF without FDA reports (8.92 and 4.96 %, respectively). The rate of overall complications in ELIF studies that were reported using neuromonitoring was lower compared to the studies that did not report using neuromonitoring (16.34 vs. 21.74 %, respectively). CONCLUSION: Although the overall complications rate for ELIF was lower compared to ALIF, ELIF is associated with a greater risk of neurological complications compared to ALIF even when used with neuromonitoring.
Authors: Rick C Sasso; Natalie M Best; Praveen V Mummaneni; Thomas M Reilly; Sajjad M Hussain Journal: Spine (Phila Pa 1976) Date: 2005-03-15 Impact factor: 3.468
Authors: Jingfeng Li; Mark L Dumonski; Qinyi Liu; Adam Lipman; Joseph Hong; Nuo Yang; Zhengshuai Jin; Yongxin Ren; Worawat Limthongkul; Jason T Bessey; John Thalgott; Greg Gebauer; Todd J Albert; Alexander R Vaccaro Journal: Spine (Phila Pa 1976) Date: 2010-12-15 Impact factor: 3.468
Authors: Fred H Geisler; Scott L Blumenthal; Richard D Guyer; Paul C McAfee; John J Regan; J Patrick Johnson; Bradford Mullin Journal: J Neurosurg Spine Date: 2004-09
Authors: Ripul Panchal; Ryan Denhaese; Clint Hill; K Brandon Strenge; Alexandre DE Moura; Peter Passias; Paul Arnold; Andrew Cappuccino; M David Dennis; Andy Kranenburg; Brieta Ventimiglia; Kim Martin; Chris Ferry; Sarah Martineck; Camille Moore; Kee Kim Journal: Int J Spine Surg Date: 2018-08-03
Authors: Matthew Scott-Young; Laurence McEntee; James Furness; Ben Schram; Wayne Hing; David Grosser; Mario Zotti Journal: Int J Spine Surg Date: 2018-08-15
Authors: Joe Iwanaga; Emre Yilmaz; Tamir Tawfik; Amir Abdul-Jabbar; Marc Vetter; Marc Moisi; Koichi Watanabe; Koh-Ichi Yamaki; R Shane Tubbs; Rod J Oskouian Journal: Cureus Date: 2018-01-29